Drug Profile
Research programme: gynaecological disorders therapeutics - Meditrina
Alternative Names: MPI 675Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Meditrina Pharmaceuticals
- Class
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Female genital diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gynaecological-disorders in USA (PO)
- 06 Feb 2008 Meditrina Pharmaceuticals has completed a global licensing agreement with AstraZeneca for use of aromatase inhibitors
- 27 Sep 2007 Preclinical trials in Gynaecological disorders in USA (PO)